128 related articles for article (PubMed ID: 22956134)
1. Identification of allosteric inhibitors of p21-activated kinase.
Viaud J; Peterson JR
Methods Mol Biol; 2012; 928():67-79. PubMed ID: 22956134
[TBL] [Abstract][Full Text] [Related]
2. [Development of PAK1 kinase inhibitors with "in silico" modeling methods].
Ferenc B; Csaba SK; Zoltán G; Jeno M; Zoltán V; György K; László O
Acta Pharm Hung; 2010; 80(4):155-61. PubMed ID: 21404476
[TBL] [Abstract][Full Text] [Related]
3. p21-Activated kinase inhibitors: a patent review.
Crawford JJ; Hoeflich KP; Rudolph J
Expert Opin Ther Pat; 2012 Mar; 22(3):293-310. PubMed ID: 22404134
[TBL] [Abstract][Full Text] [Related]
4. p21-activated kinase inhibitors.
Rudolph J; Crawford JJ; Hoeflich KP; Chernoff J
Enzymes; 2013; 34 Pt. B():157-80. PubMed ID: 25034104
[TBL] [Abstract][Full Text] [Related]
5. PAK'n it in: identification of a selective PAK inhibitor.
Bokoch GM
Chem Biol; 2008 Apr; 15(4):305-6. PubMed ID: 18420134
[TBL] [Abstract][Full Text] [Related]
6. Small molecules that allosterically inhibit p21-activated kinase activity by binding to the regulatory p21-binding domain.
Kim DJ; Choi CK; Lee CS; Park MH; Tian X; Kim ND; Lee KI; Choi JK; Ahn JH; Shin EY; Shin I; Kim EG
Exp Mol Med; 2016 Apr; 48(4):e229. PubMed ID: 27126178
[TBL] [Abstract][Full Text] [Related]
7. An allosteric kinase inhibitor binds the p21-activated kinase autoregulatory domain covalently.
Viaud J; Peterson JR
Mol Cancer Ther; 2009 Sep; 8(9):2559-65. PubMed ID: 19723886
[TBL] [Abstract][Full Text] [Related]
8. A brain serine/threonine protein kinase activated by Cdc42 and Rac1.
Manser E; Leung T; Salihuddin H; Zhao ZS; Lim L
Nature; 1994 Jan; 367(6458):40-6. PubMed ID: 8107774
[TBL] [Abstract][Full Text] [Related]
9. Inhibitors of p21-activated kinases (PAKs).
Rudolph J; Crawford JJ; Hoeflich KP; Wang W
J Med Chem; 2015 Jan; 58(1):111-29. PubMed ID: 25415869
[TBL] [Abstract][Full Text] [Related]
10. Tinkering outside the kinase ATP box: allosteric (type IV) and bivalent (type V) inhibitors of protein kinases.
Cox KJ; Shomin CD; Ghosh I
Future Med Chem; 2011 Jan; 3(1):29-43. PubMed ID: 21428824
[TBL] [Abstract][Full Text] [Related]
11. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
[TBL] [Abstract][Full Text] [Related]
12. Structure-Guided Design of Group I Selective p21-Activated Kinase Inhibitors.
Crawford JJ; Lee W; Aliagas I; Mathieu S; Hoeflich KP; Zhou W; Wang W; Rouge L; Murray L; La H; Liu N; Fan PW; Cheong J; Heise CE; Ramaswamy S; Mintzer R; Liu Y; Chao Q; Rudolph J
J Med Chem; 2015 Jun; 58(12):5121-36. PubMed ID: 26030457
[TBL] [Abstract][Full Text] [Related]
13. p21-activated kinase 4: a druggable target in the elusive oncogenic KRAS pathway?
Azmi AS; Mohammad RM
Future Med Chem; 2015; 7(1):5-7. PubMed ID: 25582328
[No Abstract] [Full Text] [Related]
14. Oncogenic Dbl, Cdc42, and p21-activated kinase form a ternary signaling intermediate through the minimum interactive domains.
Wang L; Zhu K; Zheng Y
Biochemistry; 2004 Nov; 43(46):14584-93. PubMed ID: 15544329
[TBL] [Abstract][Full Text] [Related]
15. Chemical inhibition through conformational stabilization of Rho GTPase effectors.
Deacon SW; Peterson JR
Handb Exp Pharmacol; 2008; (186):431-60. PubMed ID: 18491063
[TBL] [Abstract][Full Text] [Related]
16. 2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl} acetamide (OSU-03012), a celecoxib derivative, directly targets p21-activated kinase.
Porchia LM; Guerra M; Wang YC; Zhang Y; Espinosa AV; Shinohara M; Kulp SK; Kirschner LS; Saji M; Chen CS; Ringel MD
Mol Pharmacol; 2007 Nov; 72(5):1124-31. PubMed ID: 17673571
[TBL] [Abstract][Full Text] [Related]
17. Phosphorylation of RhoGDI by p21-activated kinase 1.
DerMardirossian CM; Bokoch GM
Methods Enzymol; 2006; 406():80-90. PubMed ID: 16472651
[TBL] [Abstract][Full Text] [Related]
18. Virtual screening filters for the design of type II p38 MAP kinase inhibitors: a fragment based library generation approach.
Badrinarayan P; Sastry GN
J Mol Graph Model; 2012 Apr; 34():89-100. PubMed ID: 22306417
[TBL] [Abstract][Full Text] [Related]
19. Computational insight into p21-activated kinase 4 inhibition: a combined ligand- and structure-based approach.
Li RJ; Wang J; Xu Z; Huang WX; Li J; Jin SF; Zhao DM; Cheng MS
ChemMedChem; 2014 May; 9(5):1012-22. PubMed ID: 24643945
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of activation of Pak1 kinase by membrane localization.
Lu W; Mayer BJ
Oncogene; 1999 Jan; 18(3):797-806. PubMed ID: 9989831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
